MedTrace Logo

PROACT - Pre-Operative Arimidex Compared To Tamoxifen

NCT00232661 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 452

Last updated 2010-02-03

No results posted yet for this study

Summary

The purpose of this study is to compare tamoxifen, versus a newer treatment, ARIMIDEX, which we already know to be well tolerated. The main objectives of this research study are to see whether using these drugs will shrink down tumours before surgery and to see if any shrinkage in the tumour affects the extent of surgery that is required.

Conditions

Interventions

DRUG

ARIMIDEX (anastrazole)

DRUG

NOLVADEX (tamoxifen)

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Arimidex Medical Science Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-08-31
Primary Completion
2003-01-31
Completion
2007-12-31

Countries

  • United States
  • Belgium
  • Brazil
  • Canada
  • Czechia
  • France
  • Hungary
  • Italy
  • Japan
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00232661 on ClinicalTrials.gov